American Society of Hirudotherapy

Safety, pharmacokinetics and pharmacodynamics of TNHH, a novel targeted neutrophil-inhibitory hirulog hybrid glycoprotein, in healthy volunteers

Phase I study published in CNS Drugs (2019)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Randomized controlled trialDrug DevelopmentSalivary PharmacologyGou ZP et al. · CNS drugs, 2019

Abstract

BACKGROUND: Targeted neutrophil inhibitory-hirulog (TNHH) is a novel hybrid glycoprotein that may be a potential drug candidate for acute ischaemic stroke. OBJECTIVE: The aim of this study was to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of TNHH in healthy volunteers and thereby determine the dose range for future clinical studies. METHODS: This randomized, placebo-controlled study was a single ascending dose design with dose levels of 0.05-1.8 mg/kg (n = 4-6 active, 2 placebos per cohort) in 68 participants. In the TNHH 0.2-1.8 mg/kg and control cohorts, pharmacokinetic and pharmacodynamic blood samples were collected over 168 h after intravenous (IV) administration. TNHH occupancy in peripheral blood neutrophils and blood coagulation were evaluated as the markers of target engagement. RESULTS: Two subjects withdrew from the trial before administration of the study treatment, 66 subjects are included in the data analysis. TNHH was well tolerated in all dose regimens. In total, five mild, self-limiting adverse events (AEs) were observed in 4 of the 66 study subjects. Dose-proportional increases in maximum plasma concentration (Cmax) and area under the curve (AUC0-t) of TNHH were observed. Traces of TNHH were excreted in urine. The elimination half-life (t½) ranged from 0.6 to 1.3 h in the eight groups with ascending dose levels. TNHH combined with CD11b/CD18 quickly achieved > 90% receptor occupancy in groups with doses above 0.2 mg/kg. The Cmax and AUC of binding TNHH with CD11b/CD18 increased with the dose. A significant prolongation with dose was observed on thrombin time (TT), and weak influences were observed on prothrombin time (PT) and activated partial thromboplastin time (APTT). CONCLUSION: TNHH was well-tolerated following IV infusion. The pharmacokinetic and pharmacodynamic characteristics of TNHH indicate that it merits clinical trials. It is recommended that the single dose of TNHH should be 1.0 mg/kg in future studies, and the expected effect may be achieved after 5-7 days of continuous administration. TRIAL REGISTRATION: The study is registered at http://www.chictr.org.cn as ChiCTR-TQR-14004752.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleRandomized Controlled TrialResearch Support, Non-U.S. Gov't
Indexed MeSH termsAdolescentAdultArea Under CurveBlood CoagulationBlood Coagulation TestsCD11b AntigenCD18 AntigensCell AdhesionCell MovementDose-Response Relationship, DrugDouble-Blind MethodFemaleFibrinolytic AgentsGlycoproteinsHealthy VolunteersHirudinsHumansInfusions, IntravenousInternational Normalized RatioMaleMiddle AgedNeutrophilsPeptide FragmentsProtein BindingRecombinant ProteinsYoung Adult

Summary

In this randomized, placebo-controlled, single ascending-dose study of TNHH, a neutrophil-inhibitory hirulog hybrid glycoprotein, in 66 healthy volunteers (0.05-1.8 mg/kg), TNHH was well tolerated, showed dose-proportional pharmacokinetics, and significantly prolonged thrombin time.

Why This Matters for Hirudotherapy

This randomized, placebo-controlled, single ascending dose study (0.05–1.8 mg/kg, n=68; 66 analyzed) evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of TNHH, described in the abstract as a 'novel hybrid glycoprotein' and 'targeted neutrophil inhibitory-hirulog' being developed for acute ischaemic stroke. TNHH was well tolerated with only mild, self-limiting adverse events; it achieved >90% CD11b/CD18 receptor occupancy above 0.2 mg/kg and produced dose-dependent prolongation of thrombin time. The abstract does not explain the term 'hirulog' or mention hirudin, leeches, or any leech-derived origin. This is an early-phase study in healthy volunteers only with no efficacy or patient outcomes. Bivalirudin (formerly Hirulog) is a synthetic peptide anticoagulant designed partly on the C-terminal sequence of hirudin, the anticoagulant of the medicinal leech (Maraganore et al., 1990); this paper studies the drug, not leech therapy.

Citation

Reference (Vancouver style)

Gou ZP, Song ZH, Chen XG, Hu XC, Wang Y, Fan K, et al. Safety, pharmacokinetics and pharmacodynamics of TNHH, a novel targeted neutrophil-inhibitory hirulog hybrid glycoprotein, in healthy volunteers. CNS Drugs. 2019;33(6):605-614. doi:10.1007/s40263-019-00628-0. PMID: 31093952

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.